Preclinical characterization of LY3962673, an orally bioavailable, highly potent, and selective KRAS G12D inhibitor

被引：3
|
作者：
Iyer, Chandrasekar
Li, Binghui
Stewart, Trent R.
Wang, Tao
Capen, Andrew
Cavitt, Rachel
Anderson, Bryan D.
Bocchinfuso, Wayne
Zhao, Gaiying
Rodriguez, Michael J.
Carballares, Santiago
Cooke, Andrew
Bondi, Robert
Burns, Lee
Kelamangalath, Lakshmi
Wallace, Ross
Kolakowski, Gabrielle
Henry, James R.
Si, Chong
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-B115
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B115
引用
收藏
页数：2
相关论文
共 50 条
  • [1] MOONRAY-01, a phase 1 study of LY3962673, a potent, orally bioavailable, and selective KRAS G12D inhibitor in KRAS G12D-mutant solid tumors
    Lakhani, Nehal J.
    Melisi, Davide
    Subbiah, Vivek
    Ammakkanavar, Natraj Reddy
    O'Reilly, Eileen M.
    Cassier, Philippe Alexandre
    Wainberg, Zev A.
    Duffy, Austin G.
    Patnaik, Amita
    Fujiwara, Yutaka
    Oberstein, Paul Eliezer
    Garcia-Carbonero, Rocio
    Wright, Jennifer
    Lin, Aimee K.
    Li, Jian
    Axelson, Michael D.
    Garrido-Laguna, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS845 - TPS845
  • [2] LY3962673, an oral, highly potent, mutant-selective, and non-covalent KRAS G12D inhibitor demonstrates robust anti-tumor activity in KRAS G12D models
    Gong, Xueqian
    Gao, Hong
    Bender, Mark H.
    Ming, Wenyu
    Zhang, Youyan
    Stewart, Trent R.
    Yu, Chun Ping
    Xu, Wei Guo
    You, Aurthur Xintian
    Bian, Wen Ting
    Li, Binghui
    Wang, Tao
    Bian, Huimin
    Tandon, Manuj
    Capen, Andrew
    Cavitt, Rachel N.
    Anderson, Bryan D.
    Bocchinfuso, Wayne
    Klippel, Anke
    Iyer, Chandrasekar
    CANCER RESEARCH, 2024, 84 (06)
  • [3] Discovery of SHR1127, an orally bioavailable, highly potent and selective KRAS G12D inhibitor
    Li, Xin
    Shen, Feng
    Zhang, Limin
    Wang, Wei
    Kong, Luyao
    Bao, Yong
    Mao, Yuchang
    Wang, Zaiyong
    Lin, Sophie
    Zhang, Zhe
    Feng, Jun
    Hu, Min
    He, Feng
    CANCER RESEARCH, 2024, 84 (06)
  • [4] INCB161734: A novel, potent, and orally bioavailable KRAS G12D selective inhibitor demonstrates antitumor activity in KRAS G12D mutant tumors
    Farren, Matthew R.
    Roman, Valerie
    Gallion, Alexandra
    Allali-Hassani, Abdellah
    Sokolsky, Alexander
    Kong, Weixi
    Smith, Amanda
    Wang, Hui
    Correa, Gina
    Deller, Marc
    Epling, Leslie B.
    Procak, Jessica
    Zhang, Guofeng
    Pecko, Katherine
    Kennedy, Keith
    Boer, Jason
    Kurzeja-Lipinski, Kerri
    Covington, Maryanne
    Chen, Kwang-Jong
    Wallower, Renee
    Rocha, Jennifer
    Pan, Rina
    Perry, Anthony
    Yuska, Brad
    Wang, Xiaozhao
    Macarron, Ricardo
    Kim, Sunkyu
    CANCER RESEARCH, 2024, 84 (06)
  • [5] Discovery of INCB159020, an Orally Bioavailable KRAS G12D Inhibitor
    Ye, Qinda
    Shvartsbart, Artem
    Li, Zhenwu
    Gan, Pei
    Policarpo, Rocco L.
    Qi, Chao
    Roach, Jeremy J.
    Zhu, Wenyu
    Mccammant, Matthew S.
    Hu, Bin
    Li, Gencheng
    Yin, Haolin
    Carlsen, Peter
    Hoang, Gia
    Zhao, Le
    Susick, Robert
    Zhang, Fenglei
    Lai, Cheng-Tsung
    Hassani, Abdellah Allali
    Epling, Leslie B.
    Gallion, Alexandra
    Kurzeja-Lipinski, Kerri
    Gallagher, Karen
    Roman, Valerie
    Farren, Matthew R.
    Kong, Weixi
    Deller, Marc C.
    Zhang, Guofeng
    Covington, Maryanne
    Diamond, Sharon
    Kim, Sunkyu
    Yao, Wenqing
    Sokolsky, Alexander
    Wang, Xiaozhao
    JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (02) : 1924 - 1939
  • [6] Preclinical characterization of LY3537982, a novel, highly selective and potent KRAS-G12C inhibitor.
    Peng, Sheng-Bin
    Si, Chong
    Zhang, Youyan
    Van Horn, Robert D.
    Lin, Xi
    Gong, Xueqian
    Huber, Lysiane
    Donoho, Gregory
    Curtis, Carmen
    Strelow, John M.
    Bocchinfuso, Wayne P.
    Guo, Deqi
    Boulet, Serge L.
    Barda, David
    Manglicmot, Danalyn
    Saflor, Melbert-Brian D.
    Wang, Jing
    Xiao, Junpeng
    Chalmers, Michael J.
    Burns, Lee
    Linder, Ryan J.
    Ackermann, Bradley L.
    Cornwell, Paul D.
    Zhou, Lian
    McCann, Denis
    Henry, James
    CANCER RESEARCH, 2021, 81 (13)
  • [7] Preclinical studies of TSN1611, a potent, selective, and orally bioavailable KRASG12D inhibitor
    Shang, Erchang
    Zhong, Boyu
    Zhang, Tony
    Dong, Chunlan
    Ma, Shengtang
    Yang, Anjiang
    Jia, Ziyang
    Zheng, Renjuan
    Li, Jing
    Fu, Han
    Lai, Liangbao
    CANCER RESEARCH, 2024, 84 (06)
  • [8] Discovery and characterization of QTX3034, a potent, selective, and orally bioavailable allosteric KRAS inhibitor
    Zhang, Yang W.
    Rominger, Dave
    Vo, Elizabeth Donohue
    Silva, Jillian M.
    Zhang, Yang J.
    Lee, Greg
    Micozzi, John
    Reid, Ben
    McDonough, Brooke
    Hospital, Audrey
    Luengo, Juan I.
    Pitt, Cameron
    Lin, Hong
    CANCER RESEARCH, 2023, 83 (08)
  • [9] Discovery and characterization of QTX3544, a potent, selective, and orally bioavailable allosteric G12V preferring multi KRAS inhibitor
    Zhang, Yang W.
    Vo, Elizabeth Donohue
    Gan, Pei
    Rominger, Dave
    Silva, Jillian M.
    Zhang, Yang J.
    Pan, Christopher
    Lee, Greg
    Micozzi, John M.
    Ben Reid
    McDonough, Brooke
    Sinha, Arghyotri
    Hospital, Audrey
    Krauth, Doug
    Luengo, Juan I.
    Kramer, Mike
    Pitt, Cameron
    Lin, Hong
    CANCER RESEARCH, 2024, 84 (07)
  • [10] Preclinical characterization of HBW-012-E, a novel, potent, selective, safe, and orally active KRAS G12D inhibitor with superior pharmacokinetic (PK) properties and anti-tumor efficacy
    Lee, Ning
    Li, Yingfu
    Liu, Guanfeng
    Li, Jiang
    Ren, Junfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345